BG-C477 for Cancer

Recruiting at 20 trial locations

Overseen By Study Director

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: BeiGene

Must not be taking: CEA-targeted ADCs, TOP1 inhibitors

Disqualifiers: Severe allergies, Brain metastasis, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

21 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety and effectiveness of a new cancer treatment called BG-C477 (also known as CEA ADC). Researchers are evaluating its effectiveness both alone and in combination with other cancer-fighting drugs for individuals with advanced solid tumors. Participants should have previously tried at least two other treatments without success. This trial suits those with a solid tumor that has been difficult to treat and who have exhausted standard treatment options. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that BG-C477 is in the early stages of testing with people. The main goal is to assess its safety and tolerability. In Phase 1, researchers are still evaluating its safety, and detailed results from earlier participants are not yet available.

Currently, this phase involves testing different doses to identify the safest one, ensuring that any side effects remain manageable. If BG-C477 progresses to later testing phases, it would indicate that safety results from this early stage are acceptable.

Researchers are also examining how BG-C477 interacts with chemotherapy to determine if it alters safety or side effects. As this is early testing, more information will emerge as the trial progresses. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

BG-C477 is unique because it represents a new direction in cancer treatment by targeting specific pathways involved in tumor growth and survival. Unlike standard chemotherapy, which often affects healthy cells along with cancerous ones, BG-C477 is designed to more precisely attack cancer cells, potentially leading to fewer side effects. Researchers are particularly excited about its potential to be used both as a monotherapy and in combination with other treatments, enhancing its versatility and effectiveness against advanced solid tumors. This focus on precision and combination therapy could represent a significant advancement over current treatment options.

What evidence suggests that this trial's treatments could be effective for cancer?

Research suggests that BG-C477 might help treat advanced solid tumors. In this trial, participants will receive BG-C477 as monotherapy in various phases to evaluate its effectiveness and safety. This potential cancer drug has shown early signs of working against tumors independently. Additionally, some participants will receive BG-C477 combined with chemotherapy, as it appears effective in this setting. While these early results are encouraging, further research is needed to confirm its effectiveness in different situations. The aim is to understand its safety and behavior in the body, guiding future studies. ^{2 6 7 8 9}

Who Is on the Research Team?

Study Director

Principal Investigator

BeiGene

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors that have grown or spread after at least two standard treatments, or when no standard treatment exists. They must be able to perform daily activities with minimal assistance (ECOG ≤1), agree to use effective birth control, and provide a tumor tissue sample. Participants need functioning major organs.

Inclusion Criteria

I agree to provide a sample of my tumor tissue.

* Phase 1a (Dose Escalation); Histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors, who were previously treated with at least 2 lines of standard systemic therapy or for whom no standard treatment is available in the medical judgment of the investigator * ≥ 1 measurable lesion as assessed by RECIST v1.1

I can sign and understand the consent form for the trial.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1a: BG-C477 Monotherapy Dose Escalation

Sequential cohorts of increasing dose levels of BG-C477 will be evaluated as monotherapy

Approximately 1 year

Phase 1a: BG-C477 Monotherapy Safety Expansion

Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in monotherapy

Approximately 1 year

Phase 1b Part A: BG-C477 Monotherapy Dose Optimization

Participants with selected advanced solid tumors will be evaluated at different dose levels of RDFEs identified in Phase 1a

Approximately 2 years

Phase 1b Part B: Combination Therapy Expansion

Sequential cohorts of increasing dose levels of BG-C477 will be evaluated in combination with chemotherapy

Approximately 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• BG-C477
• Chemotherapy

Trial Overview The study tests BG-C477's safety and effectiveness alone and combined with chemotherapy in treating solid tumors. It will assess how the body processes the drug, its impact on the body, and its ability to shrink tumors.

How Is the Trial Designed?

Group I: Phase 1b Part B: Combination Therapy Expansion Experimental Treatment 2 Interventions

Sequential cohorts of increasing dose levels of BG-C477 will be evaluated in combination with chemotherapy.

Group II: Phase 1b Part A: BG-C477 Monotherapy Dose Optimization Experimental Treatment 1 Intervention

Participants with selected advanced solid tumors will be evaluated at different dose levels of RDFEs identified in Phase 1a.

Group III: Phase 1a: BG-C477 Monotherapy Safety Expansion Experimental Treatment 1 Intervention

Selected dose levels that have been determined to be safe in Phase 1a dose escalation will be further evaluated in monotherapy.

Group IV: Phase 1a: BG-C477 Monotherapy Dose Escalation Experimental Treatment 1 Intervention

Sequential cohorts of increasing dose levels of BG-C477 will be evaluated as monotherapy.

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials

216

Recruited

32,500+

Published Research Related to This Trial

The study developed a fully human single-domain antibody (UdAb) targeting CEACAM5, which is overexpressed in various cancers, and demonstrated its potential as an effective delivery system for the cytotoxic agent monomethyl auristatin E (MMAE).

The UdAb-MMAE conjugate showed strong antitumor efficacy in multiple cancer cell lines and significantly inhibited tumor growth in mouse models without causing significant weight loss, indicating a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Zhu, XY., Li, QX., Kong, Y., et al.[2023]

In a study of 298 patients with metastatic colorectal cancer (mCRC), lower baseline carcinoembryonic antigen (CEA) serum levels were associated with better responses to bevacizumab-based therapy, showing a disease control rate of 84% in patients with CEA levels below the median compared to 60% in those above.

Patients with lower baseline CEA levels also experienced longer progression-free survival (PFS) and overall survival, with a median PFS benefit of 2.1 months and overall survival of 37.5 months versus 21.4 months for those with higher levels, indicating that CEA levels could be a useful predictor for treatment efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer. Prager, GW., Braemswig, KH., Martel, A., et al.[2022]

Antibody-drug conjugates (ADCs) have significantly advanced breast cancer treatment, with three ADCs currently approved by the FDA, enhancing therapeutic options for patients with both advanced and early-stage breast cancer.

Recent phase 3 trials (ASCENT, TULIP, and DESTINY-Breast03) demonstrated promising efficacy for newer ADCs like sacituzumab govitecan and trastuzumab deruxtecan, indicating their potential to improve patient outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development. Koster, KL., Huober, J., Joerger, M.[2022]

In a murine model of colon cancer, combining Ad-CEA vaccination with anti-PD-1 antibody significantly enhanced anti-tumor activity compared to using either treatment alone.

The combination therapy not only increased T-cell infiltration into tumors but also reduced regulatory T cells (Tregs), suggesting a more robust immune response against the cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. Sun, Y., Wang, S., Yang, H., et al.[2020]

The monoclonal anti-CEA antibody A5B7, when conjugated to CPG2, effectively targets LS174T xenografts, reaching peak concentration within 24 hours, but requires a delay of 5-6 days for prodrug injection to avoid toxicity due to residual enzyme activity in plasma.

A novel three-phase system using the galactosylated anti-CPG2 antibody SB43gal allows for prodrug administration within 24 hours after conjugate injection, resulting in a significant growth delay of the tumor after treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Sharma, SK., Bagshawe, KD., Springer, CJ., et al.[2006]

In a study of 23 patients with advanced HER2-expressing solid tumors, RC48-antibody-drug conjugate (ADC) demonstrated a promising objective response rate (ORR) of 43.5% and a median progression-free survival (PFS) of 6.0 months, indicating its potential effectiveness in this patient population.

The treatment was generally well-tolerated, with manageable adverse events such as anemia and leukopenia, and no Grade 4 adverse reactions or deaths reported, suggesting a favorable safety profile for RC48-ADC.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

RC48-ADC treatment for patients with HER2-expressing locally advanced or metastatic solid tumors: a real-world study. Wang, P., Xia, L.[2023]

The novel antibody-drug conjugate platform, Dolasynthen (DS), allows for precise optimization of drug-to-antibody ratios and site-specific conjugation, enhancing targeted drug delivery to tumors.

XMT-1660, an ADC developed using this platform targeting the B7-H4 protein, showed complete tumor regressions in various cancer models and has entered clinical development, indicating promising efficacy in treating cancers with high B7-H4 expression.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Toader, D., Fessler, SP., Collins, SD., et al.[2023]

The study demonstrated that a new fluorescently labeled chimeric anti-CEA antibody significantly improved the detection of colon cancer, providing a brighter fluorescence signal in tumor tissues compared to traditional mouse antibodies.

Fluorescence-guided surgery (FGS) using the chimeric antibody increased the complete resection rate (R0) of tumors from 86% to 96%, indicating its potential for more effective surgical outcomes in colon cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. Metildi, CA., Kaushal, S., Luiken, GA., et al.[2021]

The anti-CEA antibody C2-45 was successfully converted from IgG4 to IgG1, enhancing its biological activity for potential cancer treatment.

The new C2-45 (IgG1) variant maintained its ability to bind to the target antigen and effectively induced cytotoxic effects against CEA-expressing tumor cells, making it a promising candidate for immunotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity]. Huang, J., Shibaguchi, H., Masahide, K.[2006]

CLDN6-23-ADC is a novel antibody-drug conjugate that selectively targets the CLDN6 protein, which is highly expressed in ovarian and endometrial cancers but not in normal adult tissues, making it a promising therapeutic option.

In preclinical studies, CLDN6-23-ADC demonstrated significant antitumor efficacy, leading to robust tumor regressions and improved survival in mouse models of CLDN6-positive cancers, and it is currently being evaluated in a phase I clinical trial.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. McDermott, MSJ., O'Brien, NA., Hoffstrom, B., et al.[2023]

In a study of 266 breast cancer patients (87 with stage III and 179 with stage IV), changes in serum carcinoembryonic antigen (CEA) levels were strongly correlated with clinical response to systemic endocrine treatment, particularly in stage IV patients.

Over 50% of stage IV patients had CEA levels exceeding 6 ng/ml at the start or during the first six months of treatment, indicating that elevated CEA could be a significant marker for monitoring treatment effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Williams, MR., Turkes, A., Pearson, D., et al.[2013]

In a study of 462 patients with low-risk stage IIA colon cancer, those with elevated perioperative serum CEA levels had a higher recurrence rate (15.9%) compared to those with lower levels, indicating that high CEA levels may signify a worse prognosis.

The findings suggest that patients with high CEA levels should be considered at higher risk and may benefit from adjuvant chemotherapy, as they showed significantly higher mortality and recurrence rates compared to those with lower CEA levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer. Kim, HG., Yang, SY., Han, YD., et al.[2021]

The novel anti-CEA monoclonal antibody (MAb) R4 effectively targets human colon carcinoma cells and mediates antibody-dependent cell-mediated cytotoxicity (ADCC), showing promise for cancer treatment.

MAb R4 specifically reacts with cancerous tissues while showing no reactivity with normal tissues, indicating its potential as a diagnostic and therapeutic tool for various carcinomas, including colon, breast, and lung cancers.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cell mediated cytotoxicity of human colon carcinoma cells by a monoclonal antibody (R4) recognizing the carcinoembryonic antigen (CEA) and CEA-related molecules. Bei, R., Moretti, A., Visco, V., et al.[2019]

The study involved 8 patients with advanced metastatic carcinoma (4 colorectal and 4 ovarian) who received a radiolabelled vindesine (VDS)-anti-CEA conjugate, demonstrating that the conjugate could localize in 5 out of 8 patients after administration.

No significant toxicity or hypersensitivity reactions were observed from the radiolocalisation or the escalating doses of the conjugate, indicating that it is safe for use in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Ford, CH., Newman, CE., Johnson, JR., et al.[2019]

Citations

1. clinicaltrials.gov clinicaltrials.gov/study/NCT06596473

A Study of BG-C477 in Participants With Advanced Solid ... This new study will check how safe and helpful a potential anticancer drug called BG-C477 is. This drug will be tested by itself or combined with other ...

2. connect.careboxhealth.com connect.careboxhealth.com/en-US/trial/listing/534697

A Study of BG-C477 in Participants With Advanced Solid Tumors The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone ...

3. withpower.com withpower.com/trial/bg-c477-for-cancer-d653c

BG-C477 for Cancer · Recruiting Participants for Phase ... This Phase 1 medical study run by BeiGene is evaluating whether BG-C477 will have tolerable side effects & efficacy for patients with Solid Tumors.

4. ancora.ai ancora.ai/en/details/NCT06596473

A Study of BG-C477 in Participants With Advanced Solid ... The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ...

5. yalemedicine.org yalemedicine.org/clinical-trials/a-phase-1-first-in-human-study-of-bg-c477-in-patients-with-advanced-solid-tumors

A Multicenter, Open-Label, Phase 1a/b First-in-Human ... The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477.

6. clinicaltrials.gov clinicaltrials.gov/study/NCT06596473

NCT06596473 | A Study of BG-C477 in Participants With ... The purpose of this study is to test if BG-C477 is safe and if it works in people with your disease when it is given on its own and in combination with other ...

7. trialfinder.panfoundation.org trialfinder.panfoundation.org/en-US/trial/listing/534697

A Study of BG-C477 in Participants With Advanced Solid ... The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477.

8. cancer.gov cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00345

A Study of BG-C477 in Participants With Advanced Solid ... The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477.

9. synapse.patsnap.com synapse.patsnap.com/drug/3f46a7a43ee84ec6aadd3baa5b71d357

BG-C477 - Drug Targets, Indications, Patents ... Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients With Selected Advanced Solid Tumors. 100 ...